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Abstract 
Craniosynostosis (CS), the premature fusion of one or more cranial sutures, is a relatively common 
congenital anomaly, occurring in 3–5 per 10,000 live births. Nonsyndromic CS (NCS) accounts for up to 
80% of all CS cases, yet the genetic factors contributing to the disorder remain largely unknown. The 
RUNX2 gene, encoding a transcription factor critical for bone and skull development, is a well known CS 
candidate gene, as copy number variations of this gene locus have been found in patients with syndromic 
craniosynostosis. In the present study, we aimed to characterize RUNX2 to better understand its role in 
the genetic etiology and in the molecular mechanisms underlying midline suture ossification in NCS. We 
report four nonsynonymous variants, one intronic variant and one 18 bp in-frame deletion in RUNX2 not 
found in our study control population. Significant difference in allele frequency (AF) for the deletion 
variant RUNX2 p.Ala84-Ala89del (ClinVar 257,095; dbSNP rs11498192) was observed in our sagittal NCS 
cohort when compared to the general population (P = 1.28 × 10−6), suggesting a possible role in the 
etiology of NCS. Dual-luciferase assays showed that three of four tested RUNX2 variants conferred a gain-
of-function effect on RUNX2, further suggesting their putative pathogenicity in the tested NCS cases. 
Downregulation of RUNX2 expression was observed in prematurely ossified midline sutures. Metopic 
sites showed significant downregulation of promoter 1-specific isoforms compared to sagittal sites. 
Suture-derived mesenchymal stromal cells showed an increased expression of RUNX2 over matched 
unfused suture derived cells. This demonstrates that RUNX2, and particularly the distal promoter 
1-isoform group, are overexpressed in the osteogenic precursors within the pathological suture sites. 
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A B S T R A C T
Craniosynostosis (CS), the premature fusion of one or more cranial sutures, is a relatively common congenital
anomaly, occurring in 3–5 per 10,000 live births. Nonsyndromic CS (NCS) accounts for up to 80% of all CS cases,
yet the genetic factors contributing to the disorder remain largely unknown. The RUNX2 gene, encoding a
transcription factor critical for bone and skull development, is a well known CS candidate gene, as copy number
variations of this gene locus have been found in patients with syndromic craniosynostosis. In the present study,
we aimed to characterize RUNX2 to better understand its role in the genetic etiology and in the molecular
mechanisms underlying midline suture ossification in NCS. We report four nonsynonymous variants, one in-
tronic variant and one 18 bp in-frame deletion in RUNX2 not found in our study control population. Significant
difference in allele frequency (AF) for the deletion variant RUNX2 p.Ala84-Ala89del (ClinVar 257,095; dbSNP
rs11498192) was observed in our sagittal NCS cohort when compared to the general population
(P = 1.28 × 10−6), suggesting a possible role in the etiology of NCS. Dual-luciferase assays showed that three of
four tested RUNX2 variants conferred a gain-of-function effect on RUNX2, further suggesting their putative
pathogenicity in the tested NCS cases. Downregulation of RUNX2 expression was observed in prematurely os-
sified midline sutures. Metopic sites showed significant downregulation of promoter 1-specific isoforms com-
pared to sagittal sites. Suture-derived mesenchymal stromal cells showed an increased expression of RUNX2 over
matched unfused suture derived cells. This demonstrates that RUNX2, and particularly the distal promoter 1-
isoform group, are overexpressed in the osteogenic precursors within the pathological suture sites.
1. Introduction
The final shape of the cranium is achieved through a complex in-
teraction of multiple skull osseous elements, dura mater, and the brain.
Bands of dense fibrous tissue connecting the flat bones of the skull,
known as sutures, provide the plasticity needed for non-traumatic
passage through the birth canal and for the accommodation of the ra-
pidly growing brain in the first years of life. Premature fusion of one or
more cranial sutures results in craniosynostosis (CS), one of the most
common craniofacial anomalies that manifests with an abnormal skull
shape. CS is a heterogeneous condition with regards to both etiology
and pathogenesis, and its reported incidence varies from 3 to 5 per
10,000 live births. Mendelian mutations account for approximately
20–25% of all CS cases and are described as syndromic as they are
usually associated with additional anomalies and/or developmental
delays [1,2]. Mutations in one of at least ten genes (EFNB1, FGFR1-3,
MSX2, POR, RAB23, TCF12, ERF, and TWIST1) are associated with most
common types of syndromic CS (Apert, Crouzon, Jackson-Weiss,
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Pfeiffer, Saethre-Chotzen, Beare-Stevenson and Muenke syndromes)
[3–7]. Nonsyndromic CS (NCS), usually affecting single sutures in an
otherwise normal skull, accounts for up to 80% of all CS cases, yet the
genetic factors contributing to the disorder remain largely unknown. To
date, single gene mutations in only a few genes, namely FGFR3,
TWIST1, EFNB1, and TCF12 [8–12] have been found to cause single
suture CS, though usually in association with additional syndromic
features.
It has been shown that the development and maintenance of cranial
sutures is controlled by several regulatory factors including those in-
volved in the BMP/ TGF-β, FGF, hedgehog (HH), eph-ephrin, and Wnt
signaling pathways. These pathways converge on the same downstream
effector Runt-related transcription factor 2 (RUNX2) [13], a strong
candidate gene in CS. Copy number variations in the RUNX2 locus have
been found in CS patients. Specifically, a duplication of the RUNX2
locus on 6p21.1 was described in patients with metopic CS and minor
additional features [14,15]. RUNX2 triplication [16] and quadruplica-
tion [17] were found in patients with more complex syndromic phe-
notypes, including combined coronal and sagittal synostosis [16] or
pan-craniosynostosis [17], respectively. This observation clearly sug-
gests a dosage effect of RUNX2 mutations, with midline (metopic and
sagittal) sutures appearing to be the primary target sites of the dys-
morphic insult.
On the other hand, haploinsuficiency of RUNX2 due to loss-of-
function (LOF) mutations causes cleidocranial dysplasia, characterized
by hypo-ossification in membranous bones (i.e. calvarial bones and
clavicles), with failure of cranial suture fusion, in addition to other
anomalies [18].
These clinical correlates confirm the key role of this gene in skull
development.
RUNX2 is an osteoblast-specific transcription factor and functions as
a regulator of osteoblast differentiation [19,20]. RUNX2 is necessary in
the early stages of osteogenic differentiation (mesenchymal stromal
cells commitment and differentiation into pre-osteoblasts). During the
later stages (differentiation of pre-osteoblasts into mature osteoblasts
and then osteocytes), RUNX2 levels decrease [21–23]. RUNX2 encodes
12 alternatively spliced transcript variants, of which 7 are protein-
coding variants, 3 are destined to nonsense mediated decay, and 2 are
classified as processed transcripts (source: https://www.ensembl.org/).
RUNX2 transcripts are transcribed from two different promoters, a
distal promoter (Promoter 1, P1) and a proximal one (Promoter 2, P2)
(Fig. 1) P1 and P2 are separated by an exon and a large intron, and the
proteins derived from the the two promoters differ at the N-terminus for
19 amino acids [24,25]. In mice, P1 is activated during osteogenesis
and is required for bone formation, while P2 is expressed in both oss-
eous and non-osseous mesenchyme, thus it is not exclusively linked to
osteogenesis [26,27]. Changes in RUNX2 expression (either gain- or
loss-of-function) significantly impact osteoblastic differentiation and
skull development. This sort of site-specific effect may be due to the
chronology of skull morphogenesis and ossification, metopic suture
being the very first to complete the fusion during early perinatal stages.
Hence, the effect of RUNX2 mutations on skeletal development may
depend on the specific stage impaired by the aberrant RUNX2 dosage,
which is involved in regulating the balance of osteogenic proliferation/
differentiation in suture tissues [6].
In order to study the possible contribution of RUNX2 to NCS etio-
pathogenesis, we have characterized this gene in a cohort of patients
with sagittal and metopic NCS. In particular, we searched for coding
sequence variations occurring in patients and analyzed the differential
expression of the transcript variants bearing either of the two alter-
native promoters in patients suture tissues and in cells derived thereof.
2. Materials and methods
2.1. Patients and biospecimens
Probands affected by sagittal NCS (sNCS) and metopic NCS (mNCS)
were selected for this study. Probands were recruited from multiple
institutions collaborating within the International Craniosynostosis
Consortium (https://health.ucdavis.edu/pediatrics/boyd-genetics-lab/
index.html). The evaluation of probands was based on clinical ex-
amination by a clinical geneticist or a referring surgeon and/or review
of the medical documentation, photographs, and existing CT scans.
Paired calvarial tissue samples, from the physiological patent suture
(termed unfused) and from the prematurely fused suture were provided
by the Pediatric Neurosurgery Unit of the Fondazione Policlinico
Universitario “A. Gemelli” – IRCCS (Rome). The tissue samples were
processed for RNA extraction and cell isolation as described below. The
study was approved by the Institutional Review Board of the University
of California Davis and the Ethical Committee of the Università
Cattolica del Sacro Cuore and was conducted in accordance with the
institutional guidelines for human subject research. Informed consents
were obtained from all study participants prior to review of medical
documentation, clinical examinations and sample collection.
2.2. PCR and sequencing
DNA was extracted from blood, saliva or mouthwash according to
the manufacturer's protocol using the Gentra Puregene Blood Kit
(QIAGEN). Genomic DNA from 50 unrelated and unaffected individuals
was used for control frequency analysis. PCR primers were selected
from the published RefSeq sequence of RUNX2 gene using the Gene
Runner software (Hastings Software, Inc.). At least 100 bases of
flanking intronic sequence was included for each exon and the 5′- and
3′-untranslated regions (UTR) of the candidate gene. PCR products were
purified using ExoSap-IT (Affymetrix). Electropherograms were ana-
lyzed with the Vector NTI ContigExpress software by two independent
investigators. All observed variants were confirmed by independent
PCR and secondary sequencing using the reverse primer. For the variant
RUNX2 p.Ala84-Ala89del, independent PCR products were analyzed by
gel electrophoresis using a 2% agarose gel. RFLP analysis was also
performed for some variants to confirm the findings from their re-
spective sequencing results.
2.3. Bioinformatic and computational analysis
SNPs were considered novel if not present in the following data-
bases: NCBI dbSNP, ExAC, or 1000Genomes. Conservation across
multiple species in amino acid residues altered by mutations was done
using ClustalW software. Possible harmful effect of the SNPs were de-
termined by SIFT and PPH prediction software (SIFT, Fred Hutchinson
Cancer Research Center, Seattle, web software, http://blocks.fhcrc.org/
sift/SIFT.html; PPH, Bork Group & Sunyaev Lab, Harvard, web soft-
ware, http://genetics.bwh.harvard.edu/pph). All noncoding variants
were analyzed for predicted alteration of promoter and/or transcrip-
tional factor binding sites with the MatInspector and TESS programs
http://www.genomatix.de/cgi-bin/eldorado/main.pl and http://www.
cbil.upenn.edu/tess/, respectively [28,29]. The rVISTA program
(https://rvista.dcode.org/) was used to analyze conservation of these
variants across species in an effort to reduce false positive findings [30].
All variations were also analyzed for cryptic splice site formation using
a splice site prediction program (http://www.fruitfly.org/seq_tools/
splice.html) [31]. This was carried out using a method analogous to
promoter analysis with 50 bases flanking each side, and with the
minimum score for both the 5′ and 3′ splice sites set at 0.8. Branch A
site analysis was carried out using Gene Runner software (Hastings
Software, Inc.) for variations 5′ of the acceptor splice sites. We com-
pared the consensus sequence for the branch A site against each allele,
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flanked by 10 bases on each side. Variations located at the 3′ of each
gene were analyzed for possible alteration of the poly A site.
2.4. Cell culture
Human calvarial osteoblasts (HCO) were obtained from ScienCell
Research Laboratories (Carlsbad, CA, USA) and cultured in DMEM
(Gibco) containing 10% FBS (Atlanta Biologicals) and 1% penicillin-
streptomycin (Gibco). HCO cells were used for luciferase assay (see
further sections). Calvarium-derived mesenchymal stromal cells
(CMSC) were isolated in primary explant tissue culture from open and
fused sutures of 33 NCS patients (16 metopic and 17 sagittal), and
cultured in DMEM (Aurogene, Rome, Italy) containing 10% FBS
(Aurogene), 1% L-glutamine (Euroclone, Milan, Italy) and 1% peni-
cillin-streptomycin (Euroclone), according to standardized methods as
described [32]. Cells were characterized by cytometry and CMSC phe-
notype was confirmed (data not shown) [33]. Confluent CMSC culture
were detached by trypsin digestion and collected for RNA isolation. All
CMSC were used between the third (P3) and fourth (P4) passage of
culture.
2.5. Vector construction
Expression vectors for all RUNX2 variants were constructed using
pCMV6 and pGL-3 was used as the reporter vector. The expression
vector construct was made by amplification of human RUNX2 cDNA
from OriGene clone (RC212884), digestion with restriction enzymes
Sgfl and Mlul (New England Biolabs) and ligation into pCMV6.
Mutation variants were introduced via QuikChange Lighting Site-
Directed Mutagenesis Kit (Stratagene) according to manufacturer's in-
structions, re-ligated into pCMV6 and transformed into E. coli. E. coli
was plated on agar plates with ampicillin and surviving colonies were
purified via Qiagen Midi-Prep kits. Constructs were sequenced to con-
firm the presence of each variant.
2.6. Dual-luciferase assay
HCO cells were incubated in 96-well plates at a density of 5 × 103/
well before transfection. After growing for 24 h, cells were transfected
using Lipofectamine 3000 (Invitrogen) according to manufacturer's
instructions. Cells were co-transfected with an empty pCMV6 or a
RUNX2 variant expression vector and a firefly luciferase reporter con-
struct containing six runx2 DNA-binding elements (pOSE2-Luc) [34].
Renilla vector was used as an internal control. Luminescence was pro-
duced by the Dual-Luciferase Reporter Assay System (Promega) ac-
cording to manufacturer's protocol and measured with a Turner Bio-
Systems™ 20/20 Luminometer. All transfections trials were performed
independently 6 times in triplicate. Experimental data was analyzed by
one-way analysis of variance and P < 0.05 was considered significantly
different.
2.7. Suture tissue processing
Calvarial tissue specimens obtained from 19 patients (10 metopic, 9
sagittal) were immediately frozen upon collection and cryopreserved
until RNA extraction. The snap-frozen calvarial tissue specimens were
grinded using a mortar and pestle, before RNA isolation.
2.8. RNA isolation
Suture tissue homogenates and CMSC were lysate using TRIzol
Reagent (Invitrogen, Carlsbad, CA, USA) [33]. RNA was then isolated
using silica membrane spin columns (Direct-zol RNA Kit, Zymo Re-
search, Irvine, CA, USA), according to the manufacturer's protocol. The
yield and quality of RNA were determined using the DU 800 Spectro-
photometer (Beckman Coulter, Brea, CA, USA).
2.9. RT-qPCR
The expression of RUNX2 was analyzed in suture tissues and cells
using RT-qPCR, according to standardized methods described else-
where [32]. To also consider the alternatively spliced variants along
with the multiple promoters of the gene, different sequence-specific
oligonucleotide primer sets were designed to amplify either the total
mRNA content or the alternative transcripts (see Supplemental
Table 1). 500 ng of total RNA were used as template for cDNA synthesis
(GoScript™ Reverse Transcription System, Promega Corporation, Ma-
dison, WI, USA) and amplified by RT-qPCR using GoTaq® qPCR Master
Mix (Promega Corporation). All RT-qPCR reactions were performed in
triplicate, and the amplified signals from RUNX2 were normalized to
that of the housekeeping gene, β-ACTIN (ACTB), and the fold change
(FC) was calculated using the ΔΔCt method using the unfused suture
tissue as control in the comparison [35]. Data were analyzed using
GraphPad Prism software version 6.0. Results are presented as mean
FC ± SD. Statistical differences between groups were analyzed using
the unpaired Student's t-test. All statistics were two-tailed and the level
of significance was set at p < 0.05.
3. Results
3.1. RUNX2 variant screening
We initially sequenced the entire coding sequence of RUNX2 in a
discovery cohort composed of 20 sNCS probands. Two nonsynonymous
familial SNPs - c.751C > T (R251C) and c.1489G > A (G497S) - were
identified in the discovery cohort and were not present in 100 control
chromosomes. Based on these findings, sequencing was conducted on
an additional cohort of 191 sNCS patients and identified a total of six
variants in RUNX2, five of which were in the coding regions of the gene
(Table 1). The intronic IVS6 + 46 G > A variant was excluded from
further analyses. Bioinformatic analyses were conducted using both
SIFT and PPH prediction programs and all variants in the coding re-
gions of the gene were predicted to be damaging. Based on these pre-
dictions all 5 variants were used for further functional studies; however,
c. 1361 A > G Y454C was removed due to technical difficulties. These
variants were previously reported in known databases, such as
HapMap, NCBI or 1000Genomes.
3.2. Incidence validation of RUNX2 p.Ala84-Ala89del variant
Of the identified RUNX2 variants, RUNX2 p.Ala84-Ala89del variant
was present as heterozygous in 30% of sequenced sNCS probands. This
inframe deletion results in the removal of 6 Alanines from a poly-Ala
stretch in the glutamine-alanine (QA) domain (17Ala > 11Ala) and a
similar deletion was recently suggested as pathogenic for CCD [36]. To
validate the variant frequency among probands with sNCS and mNCS,
we screened an additional 127 sNCS probands, as well as a cohort of
191 mNCS probands by gel electrophoresis in order to compare the
RUNX2 p.Ala84-Ala89del variant frequency between the sagittal and
metopic NCS subtypes. A comparison of allele frequency (AF) between
the sNCS and mNCS cohorts versus the general population was per-
formed. Within our combined NCS cohort of 461 probands (922 alleles)
scored for RUNX2 p.Ala84-Ala89del, a total of 110 alleles were iden-
tified (11.9%) (AF = 0.119, based on Hardy-Wainberg) [37]. Using
Pearson's Chi-square test, this difference in frequency compared to that
of the general population (0.0813; gnomAD Database) was significant
(P = 2.83 × 10−5). When comparing each NCS subtype to the general
population, the AF of RUNX2 p.Ala84-Ala89del in the sNCS cohort
(AF = 0.155) was significant different (P = 1.28 × 10−6). No sig-
nificant difference in AF between the mNCS cohort (AF = 0.068) and
the general population was observed (P = 0.193), demonstrating that
the sagittal suture drove the significant difference observed in our NCS
cohort. Analyzing between NCS subtypes, the AF of RUNX2 p.Ala84-
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Ala89del between the sNCS cohort and the mNCS cohort were sig-
nificantly different (P = 3.08 × 10−4).
3.3. Functional assay of RUNX2 mutations
We performed a dual-luciferase assay in order to determine the
potential functional effect of the four RUNX2 variants. The reporter
vector for all assays was created by cloning the known RUNX2 binding
element OSE2 [34] upstream of the minimal promoter for firefly luci-
ferase (pOSE2-Luc). We used the following expression vectors: an empty
vector (pCMV6), a wild-type RUNX2 cDNA clone (WT) and four vectors
mutagenized for each of the variants R251C, D334N, G511S, and
p.Ala84-Ala89del. We were not able to create an expression vector for
the Y454C variant. Additionally, a known LOF M175R variant causing
CCD [38] was used as a control. Each assay was carried out by trans-
fecting pOSE2-Luc and one of the RUNX2 expression vectors into HCO
cells. R251C, D334N, and p.Ala84-Ala89del show statistically sig-
nificant increases in luminescence over WT (Fig. 2) with fold increases
of 1.5, 1.3, and 2.9 respectively. As expected, the empty vector pCMV6
showed minimal luminescence and luminescence with G511S and
M175R was lower as compared to WT, indicating possible LOF func-
tuality.
3.4. RUNX2 isoform analysis
We then mapped the identified sequence variants in the alternative
transcripts deriving from P1 and P2 promoters of the RUNX2 gene.
Fig. 1 shows the position of the 5 RUNX2 variants identified within the
coding sequence of the gene (see Table 1 for details of gene variants):
rs11498192 (p.Ala84-Ala89del), rs11498200 (R251C) and
rs373752642 (D334N) map in regions shared by all the coding iso-
forms, whereas rs1216479084 (Y454C) and rs11498198 (G511S) map
in an exon that is skipped in the ENST00000576263.5 splice variant
(Fig. 1). Four of the variants (R251C, D334N, Y454C and G511S) do not
appear to fall within functional/binding domains of the RUNX2 protein,
while the RUNX2 p.Ala84-Ala89del variant is within the QA domain of
the gene. The alternative promoters of the human RUNX2 are know to
drive chronologically phased transcriptional patterns during skull
morphogenesis [26]. Therefore, to assess the contribution of the dif-
ferent transcript isoforms in the ossification patterns of metopic and
sagittal sutures of NCS patients, we analyzed RUNX2 expression in
matched fused versus open (unfused) suture tissue samples, and in
matched calvarial mesenchymal stromal cells (CMSC) derived from
fused versus open sutures of patients with either sNCS or mNCS.
RUNX2 total expression was significantly reduced in both mNCS and
sNCS fused suture tissues compared to patient-matched unfused sites
(Fig. 3A). The expression of P1-derived isoforms was significantly
down-regulated in mNCS fused sutures, while the P2-derived isoforms
did not show statistically significant differences between fused and
unfused tissues of both mNCS and sNCS (Fig. 3A). In sNCS patients, P1-
derived RUNX2 isoforms were significantly overexpressed in CMSC
from fused sutures, when compared with those from the patient-mat-
ched open sutures (Fig. 3B). The total gene expression and that of the
P2-derived isoforms did not display statistically significant differences
between the two groups in sNCS (Fig. 3B). Conversely, in mNCS pa-
tients, both total and P2 isoform expression levels were significantly
higher in CMSC from fused sutures compared with those from the
matched open sutures (Fig. 3B). P1-derived isoform expression levels
showed an increasing trend in CMSC from fused sutures over unfused
ones in mNCS, though they did not reach a statistically significant
difference (Fig. 3B).
We analyzed RUNX2 expression levels in fused suture tissues and in
CMSC comparatively between mNCS versus sNCS groups. We observed
that RUNX2 expression of both total mRNA and of the P1-derived iso-
forms were significantly downregulated in mNCS fused sutures when
compared to sNCS fused sutures (Fig. 4). In suture tissues and CMSC,
P2-derived isoforms expression did not significantly change within the
two patient groups (Fig. 4). No significant change in RUNX2 total ex-
pression was observed in fused suture-derived CMSC between sNCS and
mNCS (Fig. 4). Finally, we have validated the expression of RUNX2 in
an indenpendent set of samples from unrelated patients with sagittal
CS. This time unmatched unfused sagittal suture tissues and fused sa-
gittal suture tissues from different individuals were comparatively
analyzed in different permutations. Our analysis highlighted that both
total and P1-derived RUNX2 isoform levels decrease in fused sagittal
compared with unfused sagittal sites, while the P2-derived isoforms did
not show statistically significant differences between the two groups
(Fig. 5).
4. Discussion
The RUNX2 gene encodes the master osteogenic transcription
factor, playing a crucial role in osteoblastic differentiation [22] and in
craniofacial development, specifically affecting membranous ossifica-
tion [39]. RUNX2 excessive dosage is known to reproducibly cause
syndromic craniosynostosis, mostly affecting the metopic and sagittal
sutures [14,16,17,40]. Additionally, murine models with early RUNX2
transgenic expression in mesenchymal cells display premature ossifi-
cation of skull sutures resulting in craniosynostosis, suggesting that
RUNX2 is a key player in driving the early stages of mesenchymal cells
differentiation into osteoblasts, and leading to intramembranous bone
formation during embryogenesis [41]. In this study, sequencing of
RUNX2 in NCS patients identified four nonsynonymous variants, one
intronic variant and one 18 bp deletion. All RUNX2 variants were sig-
nificantly enriched in our study cohort (P ≤ 0.05), except for G511S
and p.Ala84-Ala89del in mNCS (Table 1).
Functional studies of the RUNX2 variants based on dual-luciferase
assays showed gain-of-function (GOF) effects from three of the four
tested variants. In the RUNX2 isoform ENST00000647337.2
(NM_001278478; GRCh38), the glutamine-alanine repeats (QA) trans-
activation domain spans amino acids 49–89, and the highly
conserved Runt-homologous DNA-binding domain spans amino acids
101–229. Four coding variants (R251C, D334N, Y454C and G511S) are
outside of both the glutamine-alanine repeats (QA) transactivation
domain and the highly conserved Runt- homologous DNA binding do-
main, and are not expected to affect other functional domains. The
RUNX2 p.Ala84-Ala89del removes 6 alanines at amino acids 73–78 of
the QA domain, which is has been shown to serve as an activation
domain [42,43]. One possible effect of the RUNX2 p.Ala84-Ala89del
would be enhanced activation of RUNX2 partners or downstream tar-
gets, consistent with the observed gain-of-function. The observed GOF
effect could also be due to modification of the secondary and/or tertiary
structure of the protein that could potentially affect the binding of
RUNX2 or some of its isoforms to either the DNA of target genes or to
cofactors/additional transcription factor. This could ultimately lead to
increased expression of RUNX2 or loss of its interaction with a repressor
[44]. This deletion was previously found in 7 out of 160 alleles from
unrelated unaffected individuals [45]. In our NCS cohort, we found a
significant difference (P = 2.83 × 10−5) in the allele frequency of this
deletion compared to the general population, 0.119 vs 0.0813, re-
spectively. The difference in allele frequency was even more significant
in our sNCS subtype cohort (P = 1.28 × 10−6), suggesting that role of
this deletion in NCS may be subtype specific. Additionally, our data
suggest that this deletion may possibly contribute to the etiology of
NCS, based on the demonstrated GOF effect, although further func-
tional experiments in animal models would be necessary to confirm
this. Recently, Gustafson and colleagues identified a positive correla-
tion between increased expression of RUNX2 and insulin-like growth
factor-1 (IGF1) in calvarial osteoblasts isolated from single suture CS
patients [46]. They also demonstrated that cells with increased IGF1
expression have decreased activity the GSK3β serine/threonine kinase,
known to inhibit RUNX2. These observations enabled postulating a
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novel polygenic inheritance model for nonsyndromic CS, according to
which the role of RUNX2 in the pathogenesis of synostosis is reinforced
in the presence of either IGF1 overexpression or of GSK3β loss-of-
function [46]. This hypothesis, tested in animal models, deserves fur-
ther validation in NCS patients' cohorts.
Additionally, we noted that three of the coding variants identified in
this study (namely, p.Ala84-Ala89del, R251C and D334N) showing
GOF effects, map in regions shared by all the coding isoforms of the
RUNX2 gene, transcribed from both the distal (P1) and the proximal
(P2) promoters. Park and collaborators previously demonstrated that
the different RUNX2 transcripts bearing the two alternative promoters
are involved in different stages of skull ossification [26]. Indeed, the
proximal promoter P2 tends to be expressed during early in the pri-
mordial cartilage that is not destined to be mineralized, whereas the
distal promoter P1 seemes to contribute to later skeletogenic events
including osteoblast differentiation and maintenance, during calvarial
morphogenesis [26]. We may thus speculate that the presence of these
sequence variants would affect both early and late osteogenic events
regulated by RUNX2 during skull morphogenesis.
Conversely, the Y454C and G511A variants map in an exon that is
skipped in the ENST00000576263.5 isoform, deriving from the alter-
native splicing of the RUNX2-P1 transcript (Fig. 1). Both these variants
failed to show significant GOF effect in luciferase assay, therefore we
cannot speculate further on their functional consequence with regard to
Fig. 1. RUNX2 coding variants. The diagram shows the schematic structure of the 7 coding isoforms of RUNX2 gene (source https://www.ensembl.org/; GRCh38),
including the promoters, the coding and non-coding exons, the introns and the alternative untranslated regions at the 3′ end (3′UTRs). The large colored boxes span
the regions amplified by the RT-qPCR primer sets (see Supplemental Table 1). The red dotted lines indicate the localization of 5 identified RUNX2 mutations (see
Table 1 and text for details). (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)
Table 1
RUNX2 variants in NCS. a Represents allele frequency in our cohort based on available exon coverage (P represents significance at a level of <0.05 compared to
Global frequency); b Global frequency for non-Finnish European population based on GnomAD; * variants selected for functional analyses. p.Ala84-Ala89del was
scored in both sNCS and mNCS and the rest of the variants were scored only in the sNCS cohort.
RUNX 2 Variant Allele Frequency a SIFT Score PPH score Prediction dbSNP Global Frequency b
p.Ala84-Ala89del* 84/540 sNCS
(P = 1.28 × 10-6)
26/382mNCS
(P = 0.193)
0.00 N/A Probably damaging rs11498192 7313/89912
c. 751C > T R251C* 1/430 sNCS
(P = 1 × 10-5)
0.018 1 Damaging/probably damaging rs11498200 4/113752
c. 1000 G > A D334N* 1/428 sNCS
(P = 1 × 10-5)
0.003 0.943 Damaging/possibly damaging rs373752642 1/113524
c. 1361 A > G Y454C 1/416 sNCS
(P = 1 × 10-5)
0.00 1 Damaging/probably damaging rs1216479084 1/113192
c. 1531 G > A G511S* 2/416 sNCS
(P = 0.215)
0.07 1 Tolerated/probably damaging rs11498198 1452/128818
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transcript isoforms.
Our data showed that the expression of RUNX2 in suture tissues and
CMSC of NCS patients is consistent with its role in the membranous
ossification. Nonetheless, the expression data are inherently extremely
heterogeneous, especially in the case of suture tissues analyzed. This
shortcoming may be due to the inter-individual variability, the poor
reproducibility of the precise collection sites during surgery, and the
variable ages of patients at surgery, which ranged between 4 and
12 months (a crucial time frame of rapid growth of the postnatal brain
and skull) [47]. We have previously demonstrated that the differences
between fused/unfused suture-derived cells are reproducible across
different suture sites. All CMSC indeed express the same mesenchymal-
like phenotype, as assessed by cytometry [33]. Also, upon an in vitro
induction, CMSC homogeneously overexpress osteogenic genes (BMP2,
Osteocalcin, RUNX2, and Osterix) as a result of their osteogenic com-
mitment and differentiation, regardless of the suture site they are iso-
lated from [33]. Nonetheless, the differential expression of RUNX2
isoforms in different suture sites, reflects the different chronology of
suture fusion patterns, given the role of this master transcription factor.
Our data are consistent with previous observations indicating that the
transcript variants derived from the P1 promoter are specifically
needed during bone formation and stimulated by the osteogenic process
[26,27]. Total RUNX2 is downregulated in fused sutures of both sagittal
and metopic NCS patients, compared with unfused sutures, indicating
completion of the osteogenic process. We found significantly lower total
RUNX2 and P1-isoform levels in fused metopic sutures than in fused
sagittal suture tissues. This expression trend could reflect the different
timing of ossification that characterizes the two different suture sites:
the metopic suture completes ossification between 3 and 9 months of
age, while complete ossification of the sagittal suture may occur very
late in adult life [48]. P2 isoforms do not seem to be relevant in this
process, consistent with the extant literature [26,27].
The observed gene expression trend in suture-derived CMSC pro-
vides additional insights into the role of RUNX2 in balancing the pro-
liferation/differentiation switch. We showed that cells isolated from
fused metopic sutures, being reasonably more committed towards os-
teogenic differentiation, showed an increased expression of RUNX2
over matched unfused suture derived cells. Cells from fused sagittal
sutures exclusively overexpress the P1-transcribed isoforms compared
with the unfused suture cells. No significant differences were found
when comparing RUNX2 expression levels between cells isolated from
metopic and sagittal fused suture sites. These data suggest that, upon ex
vivo isolation, skeletogenic mesenchymal stromal cells tend to display a
similar phenotype and RUNX2 expression pattern, regardless of the
suture source. Interestingly, a previous study reported that the presence
of the common Apert FGFR2 p.P253R mutation is able to selectively
regulate the alternative splicing of P1-isoforms, inducing the con-
stitutive increase signaling of RUNX2 leading to excessive ossification
[49].
5. Conclusions
In summary, our study suggests an etiopathogenetic role for RUNX2
in the aberrant membranous ossification process occurring in at least a
subset of individuals with midline NCS. Specifically, rare mutations of
RUNX2 with significant GOF effects could contribute to a proportion of
midline NCS cases. Considering that the AF for RUNX2 p.Ala84-
Ala89del was statistically different in sNCS versus the general popula-
tion, it is plausible that its GOF effect is necessary and suture specific,
but not sufficient for the development of CS. This deletion falls in a
sequence region that is transcribed by both of the known alternative
promoters of the gene. Recent data suggesting polygenic inheritance
involving RUNX2 increased function could be further tested as a novel
etiological modality for nonsyndromic single suture CS [46]. Also, the
expression data demonstrated that RUNX2, and particularly the P1-
isoform group, are overexpressed in the osteogenic precursors within
the pathological suture sites, which could lead to accelerated differ-
entiation, resulting in premature fusion of the metopic and sagittal
sutures. Further functional studies are needed to establish how the GOF
variants affect the RUNX2 isoform expression and/or DNA binding ul-
timately contributing to NCS.
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.bone.2020.115395.
Fig. 2. Dual-luciferase assay of RUNX2 variants. Control calvarial osteoblasts were transfected with (1) pOSE2-Luc reporter vector and (2) one of five RUNX2 variants
in a pCMV6 vector with minimal promoter. Transfection of pOSE2-Luc (OSE2 binding element) alone resulted in negligible luciferase production. Six independent
replicates were tested for each construct. Renilla vectors were used as internal transfection controls for all experiments. (*) represents significance at a level of <0.05
compared to the wild-type (WT). Bars represent mean ± SE.
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derived isoforms) in patient-matched samples of both mNCS and sNCS (i.e. pairwise comparison between fused and unfused sutures from the same patient): A)
expression levels analyzed in suture tissues; B) expression levels analyzed in suture-derived calvarial mesenchymal stromal cells (CMSC). *P ≤ 0.05; **P ≤ 0.01;
***P ≤ 0.001; ****P ≤ 0.0001.
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